Who Paid My Doc
Keith Gottesdiener
Infectious Disease Rahway, NJ Medical Doctor
NPI 1821150376 CMS profile 37769
Mrl-126 East Lincoln Ave., Rahway, NJ 07065
General payments
$2,131,252
Research payments
$0
Ownership & investment interest
$1,276,689
Through program year 2025, Keith Gottesdiener of Rahway, NJ is reported in the CMS Open Payments database as having received $2,131,252 across 89 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $1,276,689 across 10 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 99th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
12 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $21,500 | 1 | |
| 2024 | General | $115,550 | 5 | |
| 2023 | General | $639,947 | 16 | |
| 2022 | General | $335,000 | 15 | |
| 2021 | General | $356,722 | 16 | |
| 2020 | General | $331,189 | 17 | |
| 2019 | General | $331,344 | 19 | |
| 2023 | Ownership | $264,455 | 2 | |
| 2022 | Ownership | $262,385 | 2 | |
| 2021 | Ownership | $240,220 | 2 | |
| 2020 | Ownership | $248,274 | 2 | |
| 2019 | Ownership | $261,355 | 2 |
Beside peers
- Keith Gottesdiener
- Infectious Disease median
- Middle half of Infectious Disease
- National median
In program year 2025, general payments to Keith Gottesdiener were reported at $21,500. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.
Show as a table
| Year | Keith Gottesdiener | Infectious Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $331,344 | $190 | $60–$862 | $163 |
| 2020 | $331,189 | $124 | $32–$606 | $114 |
| 2021 | $356,722 | $148 | $38–$905 | $132 |
| 2022 | $335,000 | $166 | $50–$834 | $149 |
| 2023 | $639,947 | $171 | $57–$787 | $160 |
| 2024 | $115,550 | $176 | $52–$752 | $164 |
| 2025 | $21,500 | $188 | $57–$766 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
89 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Infectious Disease in New Jersey
Jihad Slim
Infectious Disease · Newark, NJ
Maria Szabela
Infectious Disease · Newark, NJ
Ronald Nahass
Infectious Disease · Hillsborough, NJ
Christopher Lucasti
Infectious Disease · Somers Point, NJ
Spartaco Bellomo
Infectious Disease · Jersey City, NJ
Jack Boghossian
Infectious Disease · Bayonne, NJ
Related records
Infectious Disease in New Jersey
Practitioners in the same specialty and state, ranked by reported value.
All Infectious Disease
Everyone recorded under this specialty, nationwide.
Doctors in New Jersey
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.